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Abstract
Background: Several studies have shown that common variants in the MTNR1B gene were associated with fasting
glucose level and type 2 diabetes. The purpose of this study was to examine whether tagging single nucleotide
polymorphisms (SNPs) in the MTNR1B region were associated with type 2 diabetes and related traits in a Han
Chinese population.
Methods: We investigated the association of polymorphisms in the MTNR1B gene with type 2 diabetes by
employing a case-control study design (1118 cases and 1161 controls). Three tagging SNPs (rs10830963, rs3781637,
and rs1562444) with R
2>0.8 and minor allele frequency>0.05 across the region of the MTNR1B gene were studied.
Genotyping was performed by matrix-assisted laser desorption/ionization time-of-flight mass spectroscopy using a
MassARRAY platform.
Results: The polymorphism rs3781637 was associated with type 2 diabetes adjusted for age, sex and body mass
index (BMI) in the additive model and recessive model (OR = 1.22, 95% CI 1.01-1.46, p = 0.038 and OR = 2.81, 95%
CI 1.28-6.17, p = 0.01, respectively). In the non-diabetic controls, rs3781637 was nominally associated with plasma
triglyceride, total cholesterol and low density lipoprotein cholesterol (LDL-C) levels in the recessive model (p =
0.018, 0.008 and 0.038, respectively). After adjustment for multiple comparisons, the associations of rs3781637 with
total cholesterol and LDL-C remained significant in the recessive model (the empirical p = 0.024 and 0.045,
respectively), but the association between rs3781637 and triglyceride became non-significant (the empirical p =
0.095). The associations of rs10830963 and rs1562444 with type 2 diabetes and related traits were not significant in
the additive, dominant and recessive models.
Conclusions: The rs3781637 A/G polymorphism of the MTNR1B gene is associated with type 2 diabetes, plasma,
total cholesterol and LDL-C levels in the Han Chinese population.
Background
Circadian rhythms are closely related to metabolism,
and dysregulation of circadian rhythms may increase the
risk of diabetes [1]. The MTNR1B gene encodes a high
affinity receptor for melatonin, a hormone primarily
secreted by the pineal gland to regulate circadian
rhythm and sleep cycles [2]. Plasma melatonin follows
an opposite circadian rhythm to plasma insulin and glu-
cose, rising by night and falling by day [3]. There are
favorable evidences that circadian rhythm of melatonin
influences insulin secretion and glucose homeostasis via
its islet-specific receptor [4]. Consistently, melatonin
secretion and circadian rhythm are impaired in type 2
diabetes patients [2]. More importantly, MTNR1B inhi-
bits insulin secretion through its effect on CGMP for-
mation when activated by melatonin [5]. Therefore, the
MTNR1B gene might be involved in glucose homeosta-
sis and type 2 diabetes.
Several large-scale genome-wide association analyses
demonstrated that common variants in or near the
MTNR1B gene to be robustly associated with fasting
glucose level in European populations [6-8], with poly-
morphism rs10830963 showing the most significant
association signal [7]. Several replication studies in
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populations [14] confirmed that MTNR1B rs10830963
contributed to raised fasting glucose level and increased
risk of type 2 diabetes.
Several studies investigated the associations of
MTNR1B rs10830963 with type 2 diabetes and fasting
glucose among Han Chinese populations [15-19]. Ling
et al. first replicated the association of MTNR1B
rs10830963 with type 2 diabetes and fasting glucose in a
case-control study including 1165 type 2 diabetes cases
and 1105 normoglycaemic controls [17]. After that,
another four studies reported that MTNR1B rs10830963
was associated with type 2 diabetes and/or fasting glu-
cose in Han Chinese populations [15,16,18,19]. Whether
other common variants except rs10830963 in the
MTNR1B gene are associated with type 2 diabetes and
fasting glucose in Han Chinese population is unknown.
The aim of this study was to examine whether com-
mon polymorphisms in MTNR1B were associated with
type 2 diabetes and related traits in a Han Chinese
population.
Methods
Subjects
All participants were of Southern Han Chinese ancestry
and resided in the Shanghai metropolitan area. Type 2
diabetic inpatients (n = 1118) were recruited from the
Endocrinology and Metabolism Department of Zhong-
shan Hospital in Shanghai, which is affiliated to Fudan
University. All type 2 diabetic patients met the 1999
WHO criteria for diabetes [20], had been diagnosed
after the age of 29 years, and were treated with oral
hypoglycaemic agents and/or insulin. 1161 unrelated
non-diabetic control participants were people under-
going health examinations in Zhongshan Hospital, were
older than 40 years, and had a fasting plasma glucose <
5.6 mmol/l.
Written informed consent was obtained from all parti-
cipants and the study was approved by the ethnic com-
mittee of Zhongshan hospital, Fudan University,
Shanghai, China.
Clinical measurements
Both the diabetic patients and the controls were exten-
sively phenotyped for anthropometric and biochemical
traits related to glucose metabolism. The phenotypes
assessed in our study include height, weight, fasting glu-
cose, total cholesterol, triglyceride, high density lipoprotein
cholesterol (HDL-C) and LDL-C. BMI was calculated as
weight (kg)/height
2 (m
2).
Genotyping
We selected tagging single nucleotide polymorphisms
(SNPs) with the criteria of R
2>0.8 and minor allele
frequency (MAF)>0.05 across the region of the MTNR1B
gene (include 3kb upstream and 3kb downstream of the
gene) from the HapMap Phase II, using the pairwise
tagging model. Pairwise tagging algorithm was developed
by Carlson et al., and the detailed description was intro-
duced previously [21]. Three tagging SNPs (rs10830963,
rs3781637, and rs1562444) were selected. The genotyping
was performed by matrix-assisted laser desorption/ioniza-
tion time-of-flight mass spectroscopy using a MassARRAY
platform (MassARRAY Compact Analyzer, Sequenom,
San Diego, CA, USA).
Statistical analysis
Continuous variables are expressed as means ± standard
error of mean (SEM) and median (interquartile range).
Comparisons between groups were performed with T
testing and c
2 testing for normally distributed continuous
and categorical variables, respectively. Deviations from
the Hardy-Weinberg equilibrium were assessed by means
of c
2 testing. SNPs that were not in the Hardy-Weinberg
equilibrium were excluded from further analysis. Addi-
tive, dominant and recessive models were assumed in the
association analysis. We tested the association of the
polymorphisms with type 2 diabetes by using logistic
regression. Multivariate linear regression was used to test
the association of the polymorphisms with quantitative
traits. All models were adjusted for age, sex, and BMI.
Permutations (10,000 times) were performed for each
trait to assess empirical p values using PLINK [22] in
order to adjust the multiple comparisons. Analysis was
performed with SPSS software version 17.0.
Results
Baseline characteristics
The baseline characteristics of participants in this study
are presented in Table 1. In 2279 participants, 1118
were type 2 diabetes patients and 1161 were non-
diabetic controls. Diabetic cases were older and had
Table 1 Baseline characteristics of diabetic cases and
non-diabetic controls
Characteristic Diabetic
cases
(n = 1118)
Non-diabetic
controls
(n = 1161)
P value*
Age (years) 60.2 ± 0.37 56.5 ± 0.32 <0.001
Men (%) 44.6 42.7 0.34
BMI (kg/m
2) 24.4 ± 0.11 23.5 ± 0.09 <0.001
Fasting glucose (mmol/l) 8.17 ± 0.04 4.86 ± 0.01 <0.001
Total cholesterol (mmol/l) 4.37(3.78-5.07) 5.10(4.50-5.80) <0.001
Triglyceride (mmol/l) 1.47(1.00-2.24) 1.40(1.00-1.90) <0.001
HDL-C (mmol/l) 1.12(1.00-1.38) 1.30(1.12-1.54) <0.001
LDL-C (mmol/l) 2.38(1.92-3.01) 3.07(2.50-3.60) <0.001
Data are expressed as means ± SEM and median (interquartile range).
*p value for comparison between cases and controls.
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lower cholesterol concentrations than the non-diabetic
controls. There was no significant difference of the dis-
tribution of sex between diabetic cases and non-diabetic
controls (p = 0.34).
Associations of MTNR1B polymorphisms with type 2
diabetes
Overall, three SNPs (rs10830963, rs3781637, and
rs1562444) were selected and genotyped in the present
study. The call rates of rs10830963, rs3781637, and
rs1562444 were 98.0%, 98.5% and 98.0%, respectively.
The concordant rates of all SNPs based on 120 dupli-
cates were 100%.
rs10830963, rs3781637, and rs1562444 were in Hardy-
Weinberg equilibrium in the study population (Table 2).
The polymorphism rs3781637 was nominally associated
with type 2 diabetes adjusted for age, sex and BMI in
the additive and recessive models (p = 0.038 and 0.01,
respectively) (Table 3). After adjustment for multiple
comparisons, the association of rs3781637 with type 2
diabetes remained significant in the additive and reces-
sive models (the empirical p = 0.050 and 0.018, respec-
tively). The carriers of GG genotype was associated with
higher odds of type 2 diabetes compared with the car-
riers of AA and AG genotypes adjusted for age, sex and
BMI (OR = 2.81, 95% CI 1.28-6.17, p = 0.01) (Table 3).
The associations of rs10830963 and rs1562444 with type
2 diabetes were not significant in the additive, dominant
and recessive models (Table 3).
Associations of MTNR1B polymorphisms with quantitative
traits in non-diabetic controls
In the non-diabetic controls, the polymorphism
rs3781637 was nominally associated with plasma trigly-
ceride, total cholesterol and LDL-C levels adjusted for
age, sex and BMI in the recessive model (p = 0.018,
0.008 and 0.038, respectively) (Table 4, Figure 1). The
p values of the associations of rs3781637 with plasma
triglyceride, total cholesterol and LDL-C levels were
0.011, 0.006 and 0.036 after additional adjustment for
fasting glucose. After adjustment for multiple compari-
sons, the associations of rs3781637 with total choles-
terol and LDL-C remained significant in the recessive
model (the empirical p = 0.024 and 0.045, respec-
tively), but the association between rs3781637 and
triglyceride became non-significant (the empirical p =
0.095). The carriers of GG genotype had a significantly
higher plasma total cholesterol and LDL-C levels com-
pared with the carriers of AA and AG genotypes
adjusted for age, sex and BMI, and the effect sizes for
the GG genotype were 0.841 and 0.585 mmol/l, respec-
tively (Table 4). The polymorphism rs3781637 was not
associated with fasting plasma glucose and HDL-C
levels in the additive, dominant and recessive models
(Table 4). The associations of rs10830963 and
rs1562444 with fasting plasma glucose, plasma trigly-
ceride, total cholesterol, LDL-C and HDL-C levels
were not significant in all three models (Table 4).
Discussion
Here we reported that a common genetic variant
rs3781637 in MTNR1B was associated with type 2 dia-
betes in a Han Chinese population. The association of
rs3781637 with type 2 diabetes was found to be signifi-
cant in the additive and recessive models. In the reces-
sive model, the carriers of GG genotype were associated
to higher odds of type 2 diabetes compared with the
carriers of AA and AG genotypes (OR = 2.81). In addi-
tion, rs3781637 showed nominal association with plasma
triglyceride, total cholesterol and LDL-C levels in the
recessive model in non-diabetic controls, and the asso-
ciations of rs3781637 with total cholesterol and LDL-C
levels remained significant after adjustment for multiple
comparisons. The carriers of GG genotype were asso-
ciated to a higher total cholesterol and LDL-C levels
compared with the carriers of AA and AG genotypes. In
addition, the associations of rs3781637 with lipid levels
were independent of glucose metabolism. The associa-
tion between MTNR1B variants and lipid profile was
not reported before, and the mechanism underlying this
association remains to be determined. However, many
evidences showed that melatonin played an important
role in the lipid metabolism. Animal studies showed
that melatonin treatment significantly improved dyslipi-
demia in diabetic rats, with reductions in triglyceride
and LDL-C levels [23,24]. The administration of melato-
nin and zinc was found to improve the lipid profile in
type 2 diabetic patients [25]. A novel melatonin agonist,
NEU-P11, decreased total cholesterol and triglyceride
levels, while increased HDL-C level in obese rats [26].
Therefore, the MTNR1B gene which encoded a high
Table 2 Characteristics of SNPs genotyped in MTNR1B
SNP identification Chromosome
Position
Relation to the gene Major allele Minor allele MAF HWE
P value
1 rs10830963 92348358 Intron C G 0.40 0.13
2 rs3781637 92353418 Intron A G 0.14 0.13
3 rs1562444 92355497 3’UTR A G 0.31 0.14
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lipid metabolism.
We failed to replicate the association of rs10830963
with type 2 diabetes or fasting plasma glucose in our
Han Chinese population. However, another three case-
control studies in Shanghai Han Chinese populations
have reported the significant association of rs10830963
with type 2 diabetes and/or fasting plasma glucose
[16-18]. Inconsistent results are often seen between dif-
ferent genetic association studies. Here, population het-
erogeneity and different environmental factors are
unlikely responsible for the inconsistency between stu-
dies. Because all study populations had Han ancestry,
were from Shanghai metropolitan area, and had similar
lifestyle. In addition, the allele frequency of rs10830963
in our study is similar to those in other studies, and the
Table 3 Genotypic and allelic distribution of MTNR1B polymorphisms and association with type 2 diabetes
SNP Alleles
Major/minor
MAF Genotype Frequency
T2DM cases/controls
ORadd
(95%CI)
a
P value* ORdom
(95%CI)
b
P value* ORrec
(95%CI)
c
P value*
rs10830963 C/G 0.40 0.361/0.481/0.159 0.92 0.22 0.85 0.08 1.01 0.96
0.348/0.508/0.144 (0.81-1.05) (0.70-1.02) (0.78-1.30)
rs3781637 A/G 0.14 0.717/0.260/0.022 1.22 0.038 1.17 0.13 2.81 0.01
0.736/0.252/0.012 (1.01-1.46) (0.96-1.43) (1.28-6.17)
rs1562444 A/G 0.31 0.472/0.432/0.096 1.06 0.42 1.02 0.83 1.27 0.14
0.457/0.456/0.088 (0.92-1.22) (0.85-1.22) (0.92-1.74)
aCalculated using logistic regression, assuming an additive model adjusted for age, sex and BMI.
bCalculated using logistic regression, assuming a dominant model adjusted for age, sex and BMI.
cCalculated using logistic regression, assuming a recessive model adjusted for age, sex and BMI.
*P values shown are not corrected for multiple comparisons.
MAF: minor allele frequency in control samples; T2DM: type 2 diabetes.
Table 4 Association between MTNR1B polymorphisms and quantitative traits in non-diabetic controls
rs10830963
Genotype CC CG GG badd ± SEM
a Padd
a* bdom ± SEM
b Pdom
b* brec ± SEM
c Prec
c*
n 396 578 164
Fasting glucose (mmol/l) 4.86 ± 0.02 4.87 ± 0.02 4.84 ± 0.03 -0.009 ± 0.017 0.59 0.0004 ± 0.024 0.99 -0.033 ± 0.032 0.30
Triglyceride (mmol/l) 1.40(1.10-1.90) 1.40(1.00-1.90) 1.40(1.10-1.80) -0.062 ± 0.049 0.21 -0.079 ± 0.070 0.25 -0.080 ± 0.094 0.40
Total cholesterol (mmol/l) 5.20(4.50-5.90) 5.10(4.50-5.73) 5.10(4.50-5.80) -0.015 ± 0.045 0.74 -0.042 ± 0.063 0.50 0.022 ± 0.084 0.79
LDL-C (mmol/l) 3.10(2.54-3.64) 3.09(2.50-3.57) 3.09(2.57-3.67) -0.002 ± 0.039 0.97 -0.020 ± 0.055 0.72 0.030 ± 0.075 0.69
HDL-C (mmol/l) 1.30(1.10-1.60) 1.40(1.13-1.53) 1.40(1.14-1.50) -0.003 ± 0.014 0.84 -0.011 ± 0.019 0.57 0.010 ± 0.026 0.70
rs3781637
Genotype AA AG GG badd ± SEM
a Padd
a* bdom ± SEM
b Pdom
b* brec ± SEM
c Prec
c*
n 841 288 14
Fasting glucose (mmol/l) 4.87 ± 0.01 4.84 ± 0.02 4.78 ± 0.10 -0.037 ± 0.025 0.14 -0.035 ± 0.026 0.18 -0.129 ± 0.124 0.30
Triglyceride (mmol/l) 1.40(1.00-1.90) 1.40(1.00-1.90) 1.70(1.13-2.18) 0.032 ± 0.071 0.65 0.002 ± 0.075 0.98 0.742 ± 0.314 0.018
Total cholesterol (mmol/l) 5.10(4.50-5.80) 5.10(4.40-5.80) 5.60(5.40-6.38) -0.022 ± 0.065 0.74 -0.062 ± 0.069 0.367 0.841 ± 0.316 0.008
LDL-C (mmol/l) 3.07(2.55-3.62) 3.02(2.50-3.56) 3.36(2.81-4.26) -0.021 ± 0.057 0.71 -0.050 ± 0.060 0.40 0.585 ± 0.281 0.038
HDL-C (mmol/l) 1.30(1.13-1.53) 1.30(1.11-1.60) 1.38(1.17-1.59) -0.001 ± 0.020 0.95 0.003 ± 0.021 0.89 -0.086 ± 0.095 0.36
rs1562444
Genotype AA AG GG badd ± SEM
a Padd
a* bdom ± SEM
b Pdom
b* brec ± SEM
c Prec
c*
n 520 518 100
Fasting glucose (mmol/l) 4.86 ± 0.02 4.86 ± 0.02 4.87 ± 0.04 0.005 ± 0.018 0.79 0.005 ± 0.023 0.83 0.009 ± 0.042 0.83
Triglyceride (mmol/l) 1.40(1.00-1.90) 1.40(1.00-1.90) 1.40(0.90-1.90) 0.009 ± 0.047 0.85 0.046 ± 0.060 0.44 -0.108 ± 0.109 0.32
Total cholesterol (mmol/l) 5.10(4.50-5.80) 5.10(4.50-5.80) 5.10(4.40-5.90) -0.004 ± 0.047 0.94 -0.019 ± 0.060 0.75 0.046 ± 0.110 0.67
LDL-C (mmol/l) 3.11(2.57-3.64) 3.03(2.50-3.60) 3.00(2.59-3.58) -0.022 ± 0.042 0.60 -0.041 ± 0.053 0.44 0.020 ± 0.097 0.84
HDL-C (mmol/l) 1.30(1.13-1.51) 1.30(1.11-1.54) 1.36(1.16-1.65) 0.010 ± 0.014 0.51 0.001 ± 0.018 0.97 0.049 ± 0.033 0.14
Data are expressed as means ± SEM and median (interquartile range).
aCalculated using multivariate linear regression, assuming an additive model adjusted for age, sex and BMI.
bCalculated using multivariate linear regression, assuming a dominant model adjusted for age, sex and BMI.
cCalculated using multivariate linear regression, assuming a recessive model adjusted for age, sex and BMI.
*P values shown are not corrected for multiple comparison.
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in our study are 98.0% and 100%, respectively. Genotyp-
ing error could not be the reason for the discrepancy
between our study and other studies. Therefore, more
replication studies of MTNR1B polymorphisms in Han
Chinese and meta-analysis are needed in the future.
Recently, MTNR1B polymorphism rs10830963 was
shown to be associated with fasting glucose and home-
ostasis model assessment of bcell function (HOMA-b)
in Caucasian overweight and obese children and adoles-
cents [27], which suggests that the effects of MTNR1B
polymorphisms on glucose metabolism were not limited
to adult populations.
As diabetes is one of the risk equivalents of coronary
heart disease (CAD), and the MTNR1B polymorphism is
associated with type 2 diabetes and lipid levels in the
present study, do they also contribute to the develop-
ment of CAD? Until now, there is no report about the
association between MTNR1B polymorphisms and CAD.
Some other diabetes-related gene polymorphisms such
as KCNQ1 gene polymorphisms [28-30]and uncoupling
protein 2 (UCP2) gene polymorphisms [31] have been
proved to be associated with CAD or the risk factors of
CAD. Recently, a polymorphism rs1333049 on chromo-
some 9p21.3 was found to be associated with CAD and
coronary plaque progression in non-diabetic but not in
type 2 diabetic patients [32], implying that it affects the
development of CAD through a novel biological
pathway other than interaction with diabetes or glucose
metabolism. Whether polymorphisms in MTNR1B con-
tribute to the susceptibility of CAD, and whether they
contribute to diabetes and CAD through a common
pathway should be investigated in the future study.
There is strong epidemiologic, clinical and phenotypic
overlap between type 2 diabetes and some insulin resis-
tance-related conditions, such as polycystic ovary
syndrome (PCOS) [33]. One study investigated the rela-
tionship between MTNR1B polymorphisms and PCOS
among Chinese women, and found that rs10830963 in
MTNR1B is not only associated with susceptibility to
PCOS, but also contribute to the PCOS phenotype [34].
However, the authors didn’t provide any information
about the difference of plasma glucose between the
PCOS patients and control subjects. It is possible that
the association of MTNR1B polymorphism with PCOS
was confounded by the plasma glucose level which
tends to be higher in PCOS patients. Further studies
are needed to determine whether the association of
MTNR1B polymorphisms with PCOS is mediated
through its effect on glucose metabolism or is indepen-
dent of glucose metabolism.
Recent studies also found that MTNR1B polymorph-
isms are associated with adolescent idiopathic scoliosis
(AIS) [35,36], a complex deformity of the spine that
most commonly occurs in girls at the peripubertal per-
iod between 10 and 16 years of age. This finding is not
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Figure 1 Associations of rs3781637 with lipid levels. The upper, middle and lower lines represent the maximum, the median and the
minimum, respectively. The bottom and the top of the box represent the 25
th and 75
th percentiles, respectively. All p values shown are
calculated using multivariate linear regression, assuming a recessive model adjusted for age, sex and BMI, and are not corrected for multiple
comparisons.
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induce osteoblast differentiation from human mesenchy-
mal stem cells and plays an important role in osteogen-
esis [37,38]. Studies with animal models, such as
pinealectomized chickens [39], pinealectomized bipedal
rats [40], and bipedal C57BL/6J mice with genetically
low circulating melatonin levels [41], suggested that
melatonin deficiency could have a significant role in the
development of AIS. Besides melatonin, hormones like
leptin [42], adiponectin [43], glucagon-like peptide-1
[44] and 1, 25-dihydroxy-vitamin D [45] all effect glu-
cose metabolism and bone metabolism simultaneously.
The associations of MTNR1B rs3781637 with type 2
diabetes and lipids levels found in our study were not
reported in the previous studies, and the function of
rs3781637 is unknown. The limitation of our study is
that we didn’t do functional study of rs3781637. It is
located in the intron of MTNR1B. It may be associated
with alternative splicing of mRNA or the binding of
transcription factor and affects the expression level of
protein. Future functional study is needed to demon-
strate this. There is also no evidence that rs3781637 is
linked with any functional variant now, but future fine
mapping and resequencing of the MTNR1B gene may
detect such functional variants.
Conclusions
Our study demonstrated that MTNR1B rs3781637 A/G
polymorphism is associated with type 2 diabetes, total
cholesterol and LDL-C levels in the Han Chinese popu-
lation. These observations suggest that MTNR1B var-
iants may be involved in both glucose and lipid
metabolism, which warrants further studies using larger,
independent cohorts and a population-based approach.
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